Shares of Curis Inc. (NASDAQ:CRIS) traded down 3.8% during mid-day trading on Wednesday . The company traded as low as $2.18 and last traded at $2.28, with a volume of 736,596 shares traded. The stock had previously closed at $2.37.

A number of analysts recently issued reports on the company. Zacks Investment Research upgraded Curis from a “sell” rating to a “hold” rating in a research report on Monday. FBR & Co restated a “buy” rating on shares of Curis in a research report on Thursday, September 8th. Finally, Robert W. Baird restated an “outperform” rating and issued a $7.00 price target on shares of Curis in a research report on Wednesday, September 7th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $4.56.

The firm’s market capitalization is $305.55 million. The firm has a 50 day moving average of $1.80 and a 200-day moving average of $1.74.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/curis-inc-cris-stock-price-down-3-8.html

Curis (NASDAQ:CRIS) last posted its quarterly earnings data on Thursday, August 4th. The company reported ($0.09) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.09). The business earned $1.70 million during the quarter, compared to analysts’ expectations of $2.05 million. Curis had a negative return on equity of 65.51% and a negative net margin of 526.72%. The business’s revenue was down 19.0% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.06) earnings per share. Analysts predict that Curis Inc. will post ($0.38) EPS for the current year.

In other news, major shareholder Discovery Technologie Aurigene purchased 10,208,333 shares of the company’s stock in a transaction that occurred on Wednesday, September 7th. The stock was purchased at an average cost of $2.40 per share, for a total transaction of $24,499,999.20. Following the completion of the transaction, the insider now owns 27,328,464 shares of the company’s stock, valued at $65,588,313.60. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 6.09% of the stock is owned by insiders.

Several hedge funds have recently modified their holdings of CRIS. Barclays PLC boosted its stake in shares of Curis by 10,149.4% in the second quarter. Barclays PLC now owns 64,059 shares of the company’s stock valued at $100,000 after buying an additional 63,434 shares during the last quarter. Metropolitan Life Insurance Co. NY purchased a new stake in shares of Curis during the second quarter valued at approximately $146,000. ProShare Advisors LLC boosted its stake in shares of Curis by 1.3% in the second quarter. ProShare Advisors LLC now owns 109,812 shares of the company’s stock valued at $171,000 after buying an additional 1,418 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of Curis by 27.2% in the second quarter. Rhumbline Advisers now owns 138,986 shares of the company’s stock valued at $217,000 after buying an additional 29,751 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in shares of Curis during the first quarter valued at approximately $248,000. Hedge funds and other institutional investors own 52.36% of the company’s stock.

About Curis

Curis, Inc is a biotechnology company. The Company is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company’s drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes.

5 Day Chart for NASDAQ:CRIS

Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.